(HealthDay News) — Antihypertensive drugs are associated with an increased risk for psoriasis, according to a review and meta-analysis published online Oct. 6 in the British Journal of Clinical Pharmacology.
Gonjin Song, Ph.D., from the Ewha Womans University in Seoul, South Korea, and colleagues conducted a literature review and meta-analysis to examine the associations between antihypertensive drugs and the incidence of psoriasis. Data from 13 studies, with 6,378,116 individuals, were included for the meta-analysis, and data from eight studies, with 5,615,918 individuals, were included for the network meta-analysis.
The researchers observed a significant association for all antihypertensive drugs with psoriasis incidence. The pooled odds ratios were 1.67 (95% confidence interval, 1.31 to 2.13), 1.40 (95% confidence interval, 1.20 to 1.63), 1.53 (95% confidence interval, 1.23 to 1.89), and 1.70 (95% confidence interval, 1.40 to 2.06) for angiotensin-converting enzyme (ACE) inhibitors, ß-blockers (BBs), calcium-channel blockers (CCBs), and thiazide diuretics, respectively, in a meta-analysis. In the network meta-analysis, the corresponding odds ratios for the risk for psoriasis were 2.09 (95% confidence interval, 1.39 to 3.18), 1.35 (95% confidence interval, 0.99 to 1.91), 1.53 (95% confidence interval, 1.07 to 2.24), and 1.80 (95% confidence interval, 1.23 to 2.66) for ACE inhibitors, BBs, CCBs and thiazide diuretics.
“Based on our results, careful monitoring of cutaneous adverse events during antihypertensive drug use is recommended, with a particular focus on possible psoriasis incidence,” the authors write.
Abstract/Full Text (subscription or payment may be required)
